Synnovation Aims At Precision Oncology With $102m In Venture Backing

 
• By Joseph Haas

Third Rock Ventures is leading a $102m series A for Synnovation, a cancer-focused biotech led by several former Incyte scientists. The new firm wants to develop best-in-class drugs against validated targets.

Precision medicine
Synnovation will aim for precision medicine in cancer • Source: Shutterstock

More from Financing

More from Business